GRI Bio Inc. (GRI)vsInsmed Inc (INSM)
GRI
GRI Bio Inc.
$2.37
-2.47%
HEALTHCARE · Cap: $3.51M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
GRI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
GRI
Avoid26
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GRI
The strongest argument for GRI centers on Price/Book, Debt/Equity.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : GRI
The primary concerns for GRI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
GRI profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
GRI generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRI Bio Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
GRI Bio Inc. is a cutting-edge biotechnology company focused on revolutionizing patient care through its proprietary microbiome technology platform. With a strong emphasis on developing innovative therapies specifically targeting unmet medical needs in immunology and oncology, GRI Bio strives to tackle the underlying causes of diseases rather than just their symptoms. The company has established a robust pipeline of product candidates and strategic research partnerships, positioning it for notable growth and a leadership role in the burgeoning field of microbiome therapeutics. Committed to enhancing patient outcomes, GRI Bio is well-equipped to make significant contributions to the future of healthcare solutions.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?